LAVA Therapeutics N.V. (LVTX) Financials

LAVA Therapeutics N.V. (LVTX) reported diluted earnings per share of -$0.94 for fiscal year 2024. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

LAVA Therapeutics N.V. (LVTX) had EBITDA of -$29.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2024, LAVA Therapeutics N.V. (LVTX) had $35.0M in cash and equivalents against $4.9M in long-term debt.

LAVA Therapeutics N.V. (LVTX) has a return on equity of -90.5% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

LAVA Therapeutics N.V. (LVTX) recorded an outflow of $19.6M in free cash flow during fiscal year 2024. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

LAVA Therapeutics N.V. (LVTX) recorded an outflow of $19.5M in operating cash flow during fiscal year 2024, representing cash used by core business activities.

LAVA Therapeutics N.V. (LVTX) had $80.8M in total assets as of fiscal year 2024, including both current and long-term assets.

LAVA Therapeutics N.V. (LVTX) invested $23K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

LAVA Therapeutics N.V. (LVTX) invested $28.4M in research and development during fiscal year 2024.

LAVA Therapeutics N.V. (LVTX) had 26M shares outstanding as of fiscal year 2024.

LAVA Therapeutics N.V. (LVTX) had a current ratio of 4.40 as of fiscal year 2024, which is generally considered healthy.

LAVA Therapeutics N.V. (LVTX) had a debt-to-equity ratio of 0.18 as of fiscal year 2024. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

LAVA Therapeutics N.V. (LVTX) had a liabilities-to-equity ratio of 1.91 as of fiscal year 2024, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

LAVA Therapeutics N.V. (LVTX) had a return on assets of -31.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

At the end of fiscal year 2024, LAVA Therapeutics N.V. (LVTX) held $76.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $19.5M over that year. Dividing the one by the other, the reported balance equals about 47 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

LAVA Therapeutics N.V. (LVTX) has an Altman Z-Score of -2.67, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

LAVA Therapeutics N.V. (LVTX) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

LAVA Therapeutics N.V. (LVTX) reported a net loss of $25.1M while operations used $19.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

LAVA Therapeutics N.V. (LVTX) reported an operating loss of $29.7M against $500K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

LAVA Therapeutics N.V. (LVTX) scores 53 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.